Ładuje się......
Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib
BACKGROUND: Crizotinib is the first tyrosine kinase inhibitor approved for the treatment of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC). An increased incidence of renal cysts has been described during the crizotinib treatment. CASE PRESENTATION: We herein report th...
Zapisane w:
| Wydane w: | Int Med Case Rep J |
|---|---|
| Główni autorzy: | , , , , , , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Dove
2020
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7083626/ https://ncbi.nlm.nih.gov/pubmed/32214855 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IMCRJ.S229080 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|